Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year - Ascendis Pharma ( NASDAQ:ASND )

3 days ago

Ascendis Pharma A/S ASND released topline data on Monday from a trial that included 84 children with achondroplasia, a genetic disorder that causes dwarfism and disproportionate short stature.

Ticker	Sentiment	Impact
ASND	Somewhat Bearish	25 %